Advertisement

Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis

Published:September 22, 2016DOI:https://doi.org/10.1016/j.urology.2016.09.016

      Objective

      To compare 1-dimensional (1D) and 3-dimensional (3D) volume measurements and determine whether primary tumor (PT) burden is predictive of overall survival (OS) following cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC).

      Materials and Methods

      Records and imaging studies of patients with mRCC treated with CN from 2006 to 2015 were included, with tumor volumes measured by a faculty radiologist blinded to clinical outcomes using Advantage Workstation Volume Share (Ver 4.6, GE, Waukesha, WI).

      Results

      Complete PT and metastatic tumor volumes were measured for 67 patients. For 15 (22.3%) patients, 1D volume was within ±10% of the measured 3D volume. In 40 (59.7%) patients, the 1D calculated PT volume was >10% of the actual 3D volume.
      Fractional percentage of tumor volume (FPTV) removed during CN was calculated using the formula PT volume/(PT + met volume). FPTV was not associated with OS when analyzed as a continuous variable.
      Patients were divided into 2 groups based on previously published cut point of 90% FPTV. No differences between cohorts in age, gender, grade, subtype, number of metastatic sites, performance status, Memorial Sloan Kettering Cancer Center risk group, or International Metastatic Renal Cell Carcinoma Database Consortium risk group were identified. OS was not different between cohorts (P = .38).

      Conclusion

      1D measurements of PT diameter frequently overestimate mRCC PT volume. In patients with mRCC selected for CN, the ratio of primary to metastatic tumor does not predict OS.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Flanigan R.C.
        • Salmon S.E.
        • Blumenstein B.A.
        • et al.
        Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
        N Engl J Med. 2001; 345: 1655-1659
        • Mickisch G.H.
        • Garin A.
        • van Poppel H.
        • de Prijck L.
        • Sylvester R.
        Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
        Lancet. 2001; 358: 966-970
        • Choueiri T.K.
        • Xie W.L.
        • Kollmannsberger C.
        • et al.
        The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
        J Urol. 2011; 185: 60-66
        • Heng D.Y.C.
        • Wells J.C.
        • Rini B.I.
        • et al.
        Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
        Eur Urol. 2014; 66: 704-710
        • Abel E.J.
        • Wood C.G.
        Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
        Nat Rev Urol. 2009; 6: 375-383
        • Middleton R.G.
        Surgery for metastatic renal cell carcinoma.
        J Urol. 1967; 97: 973-977
        • Robertson C.N.
        • Linehan W.M.
        • Pass H.I.
        • et al.
        Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
        J Urol. 1990; 144 (discussion 617-618): 614-617
        • Fallick M.L.
        • McDermott D.F.
        • LaRock D.
        • Long J.P.
        • Atkins M.B.
        Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.
        J Urol. 1997; 158: 1691-1695
        • Pierorazio P.M.
        • McKiernan J.M.
        • McCann T.R.
        • Mohile S.
        • Petrylak D.
        • Benson M.C.
        Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed.
        BJU Int. 2007; 100: 755-759
        • Barbastefano J.
        • Garcia J.A.
        • Elson P.
        • et al.
        Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
        BJU Int. 2010; 106: 1266-1269
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Lubner M.G.
        • Dustin Pooler B.
        • del Rio A.M.
        • Durkee B.
        • Pickhardt P.J.
        Volumetric evaluation of hepatic tumors: multi-vendor, multi-reader liver phantom study.
        Abdom Imaging. 2014; 39: 488-496
        • Motzer R.J.
        • Mazumdar M.
        • Bacik J.
        • Berg W.
        • Amsterdam A.
        • Ferrara J.
        Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
        J Clin Oncol. 1999; 17: 2530-2540
        • Heng D.Y.C.
        • Xie W.L.
        • Regan M.M.
        • et al.
        Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
        J Clin Oncol. 2009; 27: 5794-5799
        • Culp S.H.
        • Tannir N.M.
        • Abel E.J.
        • et al.
        Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?.
        Cancer. 2010; 116: 3378-3388
        • Petrick N.
        • Kim H.J.
        • Clunie D.
        • et al.
        Comparison of 1D, 2D, and 3D nodule sizing methods by radiologists for spherical and complex nodules on thoracic CT phantom images.
        Acad Radiol. 2014; 21: 30-40
        • Heng D.Y.
        • Xie W.
        • Regan M.M.
        • et al.
        External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
        Lancet Oncol. 2013; 14: 141-148
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Pantuck A.J.
        • Belldegrun A.S.
        • Figlin R.A.
        Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?.
        Clin Cancer Res. 2007; 13: 693s-696s
        • Bedke J.
        • Kruck S.
        • Gakis G.
        • Stenzl A.
        • Goebell P.J.
        Checkpoint modulation—a new way to direct the immune system against renal cell carcinoma.
        Hum Vaccin Immunother. 2015; 11: 1201-1208
        • de Bruijn R.E.
        • Nijkamp J.
        • Noe A.
        • et al.
        Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
        Urol Oncol. 2016; 34 (e7-e13): 258